- Home
- WEA vs CGEN Comparison
WEA vs CGEN Comparison
Compare WEA & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- CGEN
- Stock Information
- Founded
- WEA 2002
- CGEN 1993
- Country
- WEA United States
- CGEN Israel
- Employees
- WEA N/A
- CGEN N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WEA Finance
- CGEN Health Care
- Exchange
- WEA Nasdaq
- CGEN Nasdaq
- Market Cap
- WEA 127.9M
- CGEN 167.4M
- IPO Year
- WEA N/A
- CGEN 2000
- Fundamental
- Price
- WEA $10.78
- CGEN $1.59
- Analyst Decision
- WEA
- CGEN
- Analyst Count
- WEA 0
- CGEN 0
- Target Price
- WEA N/A
- CGEN N/A
- AVG Volume (30 Days)
- WEA 46.1K
- CGEN 162.2K
- Earning Date
- WEA 01-01-0001
- CGEN 08-05-2025
- Dividend Yield
- WEA 7.87%
- CGEN N/A
- EPS Growth
- WEA N/A
- CGEN N/A
- EPS
- WEA N/A
- CGEN N/A
- Revenue
- WEA N/A
- CGEN $27,589,000.00
- Revenue This Year
- WEA N/A
- CGEN N/A
- Revenue Next Year
- WEA N/A
- CGEN $173.80
- P/E Ratio
- WEA N/A
- CGEN N/A
- Revenue Growth
- WEA N/A
- CGEN N/A
- 52 Week Low
- WEA $9.60
- CGEN $1.13
- 52 Week High
- WEA $11.29
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- WEA 47.39
- CGEN 44.35
- Support Level
- WEA $10.83
- CGEN $1.66
- Resistance Level
- WEA $11.04
- CGEN $1.74
- Average True Range (ATR)
- WEA 0.10
- CGEN 0.10
- MACD
- WEA -0.00
- CGEN -0.02
- Stochastic Oscillator
- WEA 25.71
- CGEN 8.00
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.